69 related articles for article (PubMed ID: 27220685)
21. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
Rychert M; Wilkins C
Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
[TBL] [Abstract][Full Text] [Related]
22. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
Rychert M; Wilkins C
Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
[TBL] [Abstract][Full Text] [Related]
23. Thirty-one psychoactive plants exempted from New Zealand's Psychoactive Substances Act 2013.
Rychert M; Wilkins C
Addiction; 2017 Jan; 112(1):181-182. PubMed ID: 27549982
[No Abstract] [Full Text] [Related]
24. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
Reuter P; Pardo B
Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
[TBL] [Abstract][Full Text] [Related]
25. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
[TBL] [Abstract][Full Text] [Related]
26. Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill.
Reuter P; Pardo B
Addiction; 2017 Jan; 112(1):25-31. PubMed ID: 27220685
[TBL] [Abstract][Full Text] [Related]
27. Worldwide legislative challenges related to psychoactive drugs.
Negrei C; Galateanu B; Stan M; Balalau C; Dumitru MLB; Ozcagli E; Fenga C; Kovatsi L; Fragou D; Tsatsakis A
Daru; 2017 Jun; 25(1):14. PubMed ID: 28578694
[TBL] [Abstract][Full Text] [Related]
28. Legal Approaches to New Psychoactive Substances: First Empirical Findings.
van Amsterdam J; Burgess N; van den Brink W
Eur Addict Res; 2023; 29(5):363-372. PubMed ID: 37557091
[TBL] [Abstract][Full Text] [Related]
29. Understanding the UK Psychoactive Substances Act.
Hill RG
Br J Clin Pharmacol; 2020 Mar; 86(3):499-504. PubMed ID: 31749206
[TBL] [Abstract][Full Text] [Related]
30. An overview of emerging and new psychoactive substances in the United Kingdom.
Beharry S; Gibbons S
Forensic Sci Int; 2016 Oct; 267():25-34. PubMed ID: 27552699
[TBL] [Abstract][Full Text] [Related]
31. A market on both "sides" of the law: The use of the hidden web for the sale of new psychoactive substances.
Wadsworth E; Drummond C; Kimergård A; Deluca P
Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28617997
[TBL] [Abstract][Full Text] [Related]
32. Managing misuse of novel psychoactive substances.
Solomon D; Grewal P; Taylor C; Solomon B
Nurs Times; 2014 May 28-Jun 3; 110(22):12-5. PubMed ID: 24984370
[TBL] [Abstract][Full Text] [Related]
33. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
Scherbaum N; Schifano F; Bonnet U
Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
[TBL] [Abstract][Full Text] [Related]
34. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
Zawilska JB; Andrzejczak D
Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
